CR10682A - Compuestos de tiazol pirazolopirimidina - Google Patents

Compuestos de tiazol pirazolopirimidina

Info

Publication number
CR10682A
CR10682A CR10682A CR10682A CR10682A CR 10682 A CR10682 A CR 10682A CR 10682 A CR10682 A CR 10682A CR 10682 A CR10682 A CR 10682A CR 10682 A CR10682 A CR 10682A
Authority
CR
Costa Rica
Prior art keywords
compounds
pirazolopirimidine
tiazol
crf1
corticotropin
Prior art date
Application number
CR10682A
Other languages
English (en)
Inventor
Chen Zhaogen
Hamdouchi Hamdouchi Chafig
James Hembre Erik
Arthur Hipsking Philip
Kenneth Myers Jason
Lee Toth James
Takakuwa Takako
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR10682A publication Critical patent/CR10682A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de Formula I:composiciones farmaceuticas de los mismos, y al uso de tales compuestos como antagonistas del receptor del factor 1 de liberacion de corticotropina (CRF1), en el tratamiento de trastornos psiquiatricos y neuroendocrinos, enfermedades neurologicas y sindrome metabolico.
CR10682A 2006-09-20 2009-03-20 Compuestos de tiazol pirazolopirimidina CR10682A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20

Publications (1)

Publication Number Publication Date
CR10682A true CR10682A (es) 2009-08-13

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10682A CR10682A (es) 2006-09-20 2009-03-20 Compuestos de tiazol pirazolopirimidina

Country Status (33)

Country Link
US (1) US8030304B2 (es)
EP (1) EP2094709B1 (es)
JP (1) JP5161226B2 (es)
KR (1) KR101088239B1 (es)
CN (1) CN101516887B (es)
AR (1) AR062886A1 (es)
AT (1) ATE481405T1 (es)
AU (1) AU2007297421B2 (es)
BR (1) BRPI0717023B8 (es)
CA (1) CA2663511C (es)
CL (1) CL2007002693A1 (es)
CR (1) CR10682A (es)
CY (1) CY1110854T1 (es)
DE (1) DE602007009305D1 (es)
DK (1) DK2094709T3 (es)
EA (1) EA015179B1 (es)
ES (1) ES2350282T3 (es)
HR (1) HRP20100516T1 (es)
IL (1) IL197614A (es)
MA (1) MA30798B1 (es)
MX (1) MX2009003125A (es)
MY (1) MY146388A (es)
NO (1) NO20091489L (es)
NZ (1) NZ575572A (es)
PE (1) PE20081377A1 (es)
PL (1) PL2094709T3 (es)
PT (1) PT2094709E (es)
RS (1) RS51545B (es)
SI (1) SI2094709T1 (es)
TN (1) TN2009000095A1 (es)
TW (1) TWI402269B (es)
UA (1) UA96458C2 (es)
WO (1) WO2008036579A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR073708A1 (es) 2008-10-02 2010-11-24 Lilly Co Eli Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IL304134B2 (en) 2014-01-21 2025-04-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
AU2017324942B2 (en) 2016-09-07 2022-01-27 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-Tau and improve cognition
TWI803504B (zh) * 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
BR112020024062A2 (pt) 2018-04-27 2021-02-09 Spruce Biosciences, Inc. métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
EP4069697B1 (en) * 2019-12-04 2025-07-16 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
EP4656192A3 (en) * 2020-08-12 2026-03-11 Spruce Biosciences, Inc. Tildacerfont and derivatives thereof for treating polycystic ovary syndrome
EP4203964A1 (en) 2020-08-26 2023-07-05 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
IL305952A (en) 2021-03-19 2023-11-01 Crinetics Pharmaceuticals Inc Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
EP4402142A4 (en) * 2021-11-19 2025-07-23 Spruce Biosciences Inc CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
ATE336495T1 (de) * 1996-02-07 2006-09-15 Neurocrine Biosciences Inc Pyrazolopyrimidine als crf rezeptor-antagonisten
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
BR9710544A (pt) * 1996-07-24 1999-08-17 Du Pont Pharm Co M-todo de tratamento composto e composi-Æo farmac-utica
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
YU23602A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
DE60218434T2 (de) * 2001-03-13 2007-11-08 Bristol-Myers Squibb Pharma Co. 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
CN1938309B (zh) 2003-12-22 2011-11-09 史密斯克莱.比奇曼（科克）有限公司 Crf受体拮抗剂及其相关方法

Also Published As

Publication number Publication date
EP2094709B1 (en) 2010-09-15
NZ575572A (en) 2011-10-28
CA2663511C (en) 2012-12-04
CY1110854T1 (el) 2015-06-10
TN2009000095A1 (en) 2010-08-19
DK2094709T3 (da) 2010-12-06
WO2008036579A1 (en) 2008-03-27
ATE481405T1 (de) 2010-10-15
JP2010504344A (ja) 2010-02-12
MX2009003125A (es) 2009-05-28
HK1132505A1 (en) 2010-02-26
IL197614A (en) 2012-10-31
CN101516887B (zh) 2011-11-02
AR062886A1 (es) 2008-12-10
PE20081377A1 (es) 2008-09-18
CN101516887A (zh) 2009-08-26
EA015179B1 (ru) 2011-06-30
TWI402269B (zh) 2013-07-21
CL2007002693A1 (es) 2008-04-18
SI2094709T1 (sl) 2011-01-31
MY146388A (en) 2012-08-15
EA200970303A1 (ru) 2009-10-30
EP2094709A1 (en) 2009-09-02
KR20090052366A (ko) 2009-05-25
MA30798B1 (fr) 2009-10-01
US8030304B2 (en) 2011-10-04
KR101088239B1 (ko) 2011-11-30
BRPI0717023B8 (pt) 2021-05-25
US20100222339A1 (en) 2010-09-02
JP5161226B2 (ja) 2013-03-13
PL2094709T3 (pl) 2011-02-28
BRPI0717023B1 (pt) 2019-11-19
AU2007297421A1 (en) 2008-03-27
BRPI0717023A2 (pt) 2014-03-11
TW200821312A (en) 2008-05-16
RS51545B (sr) 2011-06-30
NO20091489L (no) 2009-04-16
PT2094709E (pt) 2010-10-04
AU2007297421B2 (en) 2012-03-08
HRP20100516T1 (hr) 2010-10-31
CA2663511A1 (en) 2008-03-27
IL197614A0 (en) 2009-12-24
DE602007009305D1 (de) 2010-10-28
ES2350282T3 (es) 2011-01-20
UA96458C2 (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
CR10682A (es) Compuestos de tiazol pirazolopirimidina
CY1109069T1 (el) Ενωσεις ιμιδαζοπυριδαζινης
MX2009003098A (es) Compuestos de tiofen pirazolopirimidina.
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
CO6382124A2 (es) Antagonistas del receptor ccr2 y usos de los mismos
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
IL210071A0 (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
CU20100159A7 (es) Compuestos
UY28752A1 (es) Agentes terapeuticos
CR20120097A (es) Nuevos antagonistas de pirimidinhepcidina y triazinhepcidina
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
CR10387A (es) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
DE602007005387D1 (de) Ptors
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
DOP2009000047A (es) Tiazol pirazolopirimidinas como antagonistas del receptor crf1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)